Abstract
Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Current Molecular Pharmacology
Title:Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Volume: 5
Author(s): Tom Hsun-Wei Huang and Basil D. Roufogalis
Affiliation:
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Abstract: Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Export Options
About this article
Cite this article as:
Hsun-Wei Huang Tom and D. Roufogalis Basil, Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs), Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020241
DOI https://dx.doi.org/10.2174/1874467211205020241 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Current Vascular Pharmacology Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists
Current Vascular Pharmacology Formulation Optimization of Human Insulin Loaded Microspheres for Controlled Oral Delivery Using Response Surface Methodology
Endocrine, Metabolic & Immune Disorders - Drug Targets Mucoadhesivity Characterization of Isabgol Husk Mucilage Microspheres Crosslinked by Glutaraldehyde
Current Drug Delivery Moxifloxacin-induced Hypoglycemia in a Non-diabetic Patient
Current Drug Safety Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus
Current Drug Safety Understanding the Mechanism and Prevention of Arterial Occlusive Thrombus Formation by Anti-Platelet Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Melanocortin - 4 Receptor Agonists for the Treatment of Obesity
Current Topics in Medicinal Chemistry Neurovascular Role of Sympathetic Nervous System and Beta-Adrenoceptor Polymorphisms in Obesity and Hypertension
Current Hypertension Reviews The Genetic Basis of Glucose Homeostasis
Current Diabetes Reviews